NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended dose of NC-6004 according to the
dose-limiting toxicity (DLT) in combination with Gemcitabine, and to assess the efficacy,
safety and tolerability.